Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

STOCK BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2017

A summary of the stock option activity and related information for the Plans for the six months ended June 30, 2017 is as follows:

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2017		217,426		$	91.33			$	-
Grants		240,000		$	4.67			$	-
Exercised		-
Forfeitures or expirations		(23,968	)		110.29
Outstanding at June 30, 2017		433,458		$	42.30		8.75	$	22,500

Vested and expected to vest at June 30, 2017		433,458		$	42.30		8.75	$	-
Exercisable at June 30, 2017		139,728		$	103.95		6.98	$	-

The assumptions used in the valuation of stock options granted during the six months ended June 30, 2017 and 2016 were as follows:

	Six Months Ended June 30, 2017		Six Months Ended June 30, 2016
Risk-free interest rate		1.77% to 2.29%		0.85% to 1.86%
Expected term of option		5.00 to 7.91 years		6.00 to 9.06 years
Expected stock price volatility		76.61% to 77.36%		73.46% to 81.59%
Expected dividend yield	$	0.0	$	0.0

The following table summarizes the restricted stock activity for the six months ended June 30, 2017:

Restricted stock units as of January 1, 2017	11,250
Granted	-
Forfeited	-
Vested	(11,250	)
Unvested restricted stock units as of June 30, 2017	-